REG - Immupharma PLC - Appointment of Independent Non-Executive Director

ImmuPharmaAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251013:nRSM0007Da&default-theme=true

RNS Number : 0007D  Immupharma PLC  13 October 2025

13 October 2025

ImmuPharma PLC

("ImmuPharma" or the "Company")

Appointment of Independent Non-Executive Director

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development
company, is delighted to announce the appointment of Ketan Patel to the Board,
as an independent Non-Executive Director. The appointment is with immediate
effect.

Ketan is an experienced investment professional and brings extensive expertise
in financial markets with a focus in the UK healthcare and life science
sectors. He has been a long-term investor in UK markets, as an analyst and
Fund Manager, running institutional, retail and charity mandates. Ketan
started his career at JP Morgan, before moving to Insight Investment where he
was a global Pharmaceutical and Healthcare analyst and spent over 20 years at
EdenTree Investment Management where he was responsible for UK equity and
global equity income strategies delivering consistent upper quartile
performance.

Ketan combines rigorous fundamental analysis with risk-focused investment
strategies. He is also a published thought leader on sustainability and
investment themes,

Ketan is a CFA Charterholder. He also holds an MSc Economic History, from
London School of Economics, MSc Geography from King's College London and BA
(Hons) History and Geography from Queen Mary University, London.

Tim McCarthy, Chief Executive Officer of ImmuPharma, said:

"We are extremely pleased to welcome Ketan to our Board. His extensive
expertise in the global pharmaceutical and life science sectors and strong
investment acumen will be invaluable to ImmuPharma.

 

Importantly, Ketan's appointment, at this time, brings a unique perspective to
the Board, as we concentrate on future strategic partnerships and commercial
deals across our product portfolio and in particular, our lead auto-immune
platform technology, P140. In addition, Ketan's investment management
experience will greatly assist us in expanding our institutional shareholder
base."

 

Ketan Patel, commented:

"After nearly three decades of investing in mid and small cap UK companies
with a focus on healthcare and life science, I am delighted to be joining the
ImmuPharma team at this pivotal stage of their journey and look forward to
contributing to the future success of the business."

 

Additional information:

 

The following information is disclosed pursuant to Schedule Two paragraph (g)
of the AIM Rules for Companies:

 

Ketan Ratna Kanji Patel, aged 52, holds or has previously held the following
directorships:

 

 Current directorships and/or partnerships             Former directorships and/or partnerships (within the last five years):
 Global Asset and Property Management Limited          None

 Whitefriars Property and Asset Management Limited

 Albion House Farringdon Exchange Management Limited

 

Ketan Patel holds no shares in the Company.

Save for the information above, there are no further disclosures to be made
in accordance with Rule 17, Schedule 2(g) of the AIM Rules for Companies in
respect of the appointment.

This announcement contains inside information as stipulated under the UK
version of the Market Abuse Regulation no 596/2014 which is part of English
law by virtue of the European (withdrawal) Act 2018, as amended.  On
publication of this announcement via a regulatory information service, this
information is considered to be in the public domain.

 

 For further information please contact:

ImmuPharma PLC (www.immupharma.co.uk (http://www.immupharma.co.uk) )  +44 (0) 207 206 2650

 Tim McCarthy, Chief Executive Officer

 Lisa Baderoon, Head of Investor Relations                             + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                               +44 (0) 203 368 3550

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)

 Patrick Claridge, Bob Pountney                                        +44 (0) 20 3650 3650

 SI Capital (Joint Broker)                                             +44 (0) 1483 413500

 Nick Emerson

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives.

For additional information about ImmuPharma please visit www.immupharma
(https://www.immupharma.co.uk/) .co.uk

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFFAFUSEISEFS



            Copyright 2019 Regulatory News Service, all rights reserved